Passage BIO, Inc.(PASG)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 35 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
PASG Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Passage BIO, Inc. (PASG), a Healthcare sector company. PASG is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 35 institutional filers currently hold this stock. Top institutional holders of PASG by reported 13-F value include Lynx1 Capital Management, VANGUARD CAPITAL MANAGEMENT, BALYASNY ASSET MANAGEMENT L.P., based on the most recent SEC filings. PASG trades on the Nasdaq exchange and files with the SEC under CIK 1787297. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PASG daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Passage BIO, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-7.8M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
+29.7% YoYOperating Income
+30.0% YoYEPS (Diluted)
+31.8% YoYTotal Assets
-39.2% YoYOp. Cash Flow
+34.3% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-45.5M +29.7% | $-64.8M +36.5% | $-102.1M +25.0% | $-136.1M +26.6% | $-185.4M -65.2% | $-112.2M |
| Operating Income | $-49.3M +30.0% | $-70.4M +35.0% | $-108.4M +21.7% | $-138.4M +25.5% | $-185.7M -64.5% | $-112.9M |
| EPS (Diluted) | $-14.35 +31.8% | $-21.04 -1031.2% | $-1.86 +25.6% | $-2.50 +28.2% | $-3.48 -19.6% | $-2.91 |
| Total Assets | $62.3M -39.2% | $102.4M -32.0% | $150.5M -38.2% | $243.5M -31.4% | $355.1M +8.3% | $328.0M |
| Operating Cash Flow | $-31.5M +34.3% | $-48.0M +38.7% | $-78.3M +33.8% | $-118.2M +6.8% | $-126.9M -57.6% | $-80.5M |
| Free Cash Flow | — | $-48.0M | — | — | — | — |
Get alerted when PASG's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Passage BIO, Inc. including:
Top Institutional Holders of PASG
Lynx1 Capital Management LP
$3.3M673,759 shVANGUARD CAPITAL MANAGEMENT LLC
$556.1K113,964 shBALYASNY ASSET MANAGEMENT L.P.
$522.3K107,025 shIkarian Capital, LLC
$485.6K99,517 shYiheng Capital Management, L.P.
$420.2K86,097 shRENAISSANCE TECHNOLOGIES LLC
$233.7K47,892 shErste Asset Management GmbH
$197.2K40,665 shGEODE CAPITAL MANAGEMENT, LLC
$180.7K37,026 shVerdad Advisers, LP
$150.0K30,728 shBOOTHBAY FUND MANAGEMENT, LLC
$138.8K28,439 sh
| Fund | Value | Shares |
|---|---|---|
| Lynx1 Capital Management LP | $3.3M | 673,759 |
| VANGUARD CAPITAL MANAGEMENT LLC | $556.1K | 113,964 |
| BALYASNY ASSET MANAGEMENT L.P. | $522.3K | 107,025 |
| Ikarian Capital, LLC | $485.6K | 99,517 |
| Yiheng Capital Management, L.P. | $420.2K | 86,097 |
| RENAISSANCE TECHNOLOGIES LLC | $233.7K | 47,892 |
| Erste Asset Management GmbH | $197.2K | 40,665 |
| GEODE CAPITAL MANAGEMENT, LLC | $180.7K | 37,026 |
| Verdad Advisers, LP | $150.0K | 30,728 |
| BOOTHBAY FUND MANAGEMENT, LLC | $138.8K | 28,439 |
More Healthcare Companies
View all Healthcare →Put PASG on your watchlist
Track score changes the day Passage BIO, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PASG a good stock to buy?
13F Pro's AI-powered analysis of Passage BIO, Inc. (PASG) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PASG are available on the PASG stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PASG is classified as a small company.
Which hedge funds own PASG?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PASG. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Passage BIO, Inc.'s investment landscape.